

Collaborative Working Project Executive Summary

St Georges Hospital NHS Foundation Trust Haematology Capacity and Resource Service Improvement Project

Project Title:

A Collaborative Working Agreement between St. George's National Health Service Foundation Trust (NHSFT) and Johnson and Johnson Innovative Medicines UK to work in partnership to address and improve the capacity and resource challenges with the trust haematology service to deliver optimum management of their myeloma population.

Partner Organisations:

St. Georges NHS Foundation Trust, Blackshaw Road, Tooting, London SW17 0QT

Johnson and Johnson Innovative Medicines UK, 50-100 Holmers Farm Way, High Wycombe, Bucks HP12 4EG.

Project Rationale:

The St. George's NHSFT Haematology Service faces significant capacity and resource challenges that impacts its ability to deliver an optimum service and care for their Multiple Myeloma (MM) patients. Currently operating at maximum capacity, the haematology unit state MM patients are experiencing delays in accessing best medical care, potentially impacting both health outcomes and satisfaction with their care.

The Haematology Service have identified a need for a solution/s to enable current and future MM demands to be met. All options are to be considered including assessments of workforce resource, a refined day units service and/ or an ambulatory care service model.

Project Period:

Dec 2025 – Mar 2026.

Project Objectives:

St George's NHSFT Haematology Service to work in collaboration with Johnson and Johnson Innovative Medicines UK to qualify and quantify the challenges for the Trust MM service to deliver optimum treatment for the current and future MM population. The project will develop solutions that will support delivery of optimum MM patient care as measured by agree measurement criteria.

If identified solutions(s) are accepted and agreed through the project, a Case for Change will be developed by St George's NHSFT Haematology Service and presented to the necessary trust decision makers.

Patient Specific:

Based on a successful project and implementation, a reduction in time for patients to access appropriate treatments is anticipated. Additionally, a reduction in delay for patients for follow-up and review of their treatment thereby having a potential to reduce complications associated with their treatment, and an improvement in patient experience by ensuring a quicker more streamlined process to treatment decisions.

Trust Specific:

Greater capacity to manage the current and future increase on demand on the MM service. Solutions will be focussed on increasing capacity, enable timely treatment delivery, and support delivery of NHS treatment targets for the current / future MM patient population.

An effective service can improve staff motivation and retention and reduce staff stress from dealing with increasing workload pressures.

Johnson and Johnson company specific:

An example of a successful collaboration with the NHS will demonstrate that a Company collaboration can help to identify efficiencies and solutions which, if implemented could build capacity, improve optimal patient flow, treatment and patient and staff experience.

The Company can use the collaboration as a platform to develop and scale similar solutions across other health economies including in other London trusts.

Contact Details

Johnson and Johnson Innovative Medicines UK: Maria Walsh, Business Unit Director
Oncology

St. George's NHSFT: Dr. Fenella Willis, Consultant Haematologist